NCT00723502已完成2 期
An Open-Label, Randomized, Multicenter, Two-Arms Efficacy and Safety Study of 14 Days Treatment With Finafloxacin 400 mg b.i.d. Plus Amoxicillin 1000 mg b.i.d.Versus Finafloxacin 400 mg b.i.d. Plus Esomeprazole 40 mg b.i.d. in Patients With Helicobacter Pylori Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Eradication of Helicobacter pylori
研究概览
简要总结
The primary objective of this study is to compare the H. pylori eradication rates with Finafloxacin in combination with Amoxicillin or Esomeprazole.
The secondary objective is to evaluate and compare the safety and tolerability of multiple oral doses of Finafloxacin plus Amoxicillin versus Finafloxacin plus Esomeprazole.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients of 18 to 70 years old, with dyspepsia or dyspeptic symptoms.
- •The patient must understand the nature of the study and must provide written informed consent.
- •Each patient must be able to communicate with study personnel.
- •Gastroscopic confirmation of H. pylori infection by Rapid Urease Test.
- •Positive Urea Breath Test.
- •Absence of blood in stools.
排除标准
- •Gastroscopic confirmation of gastric ulcers.
- •History of Zollinger-Ellison syndrome.
- •Gastroesophageal Reflux Disease (GERD).
- •Subtotal gastrectomy or vagotomy in medical history.
- •Pyloric stenosis.
- •Previous H. pylori eradication therapy.
- •Patients likely to need to take one of the following medication within two weeks prior to and during the study period:
- •any other antibiotic than the study medication;
- •any other proton-pump inhibitor than the study medication;
- •NSAIDs including aspirin and glucocorticoids;
- •Patients taking antacids and/or H2-blockers during the study period.
- •Patients taking bismuth compound within four weeks prior to and during the study period.
- •Patients with psychiatric, neurological, or behavioral disorders that may interfere with the conduct or interpretation of the study.
- •Patients with severe concomitant disease of the cardiovascular, pulmonic, hepatic, renal, hematological, lymphatic, metabolic, and endocrine system.
- •Clinically significant serious unstable physical illness: treated, controlled and thus stable hypertension is not considered an exclusion criterion.
- •Patients with known uncontrolled hypertension or symptomatic hypotension.
- •Patients who are immunocompromised.
- •Patients with malignant disease of any kind except Basalioma.
- •Patients showing clinically significant abnormal vital signs.
- •Patients with clinically significant abnormal ECG findings.
- •Clinically significant abnormal laboratory data at Screening, or any abnormal laboratory value that could interfere with the assessment of safety.
- •Exposure to any investigational drug within 30 days prior Screening.
- •Known hypersensitivity or contraindication to the use of fluoroquinolones.
- •Prior participation in Finafloxacin study.
- •Pregnant or nursing woman, or woman of childbearing potential who is not using an effective contraceptive method during the study, e.g. oral (stable doses for at least three months prior to Screening) or injectable (stable doses for at least two months prior to Screening) contraceptives, implantation of levonorgestrel system and intrauterine devices (for at least two months prior Screening), barrier methods (combination of diaphragm and spermicide or condom and spermicide).
- •Current diagnosis or known history of substance abuse.
- •Site personnel and their immediate families, defined as their spouse, parent, child, grandparent, or grandchild.
- •Reasonable likelihood for non-compliance with the protocol or any other reason that, in the investigator's opinion, prohibits the inclusion of the patient into the study.
研究组 & 干预措施
1
Experimental
干预措施: Finafloxacin + Amoxicillin (Drug)
2
Experimental
干预措施: Finafloxacin + Esomeprazole (Drug)
结局指标
主要结局
Eradication of Helicobacter pylori
时间窗: 14 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
A Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional DyspepsiaFunctional DyspepsiaNCT02162316Chung-Ang University Hosptial, Chung-Ang University College of Medicine136
已完成
3 期
Eradication of H. Pylori Infection With MoxifloxacinHelicobacter Pylori Infection, Susceptibility toHelicobacter Pylori InfectionNCT05863858Iyad Naeem Muhammad, PhD162
已完成
3 期
Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.Helicobacter Pylori GastritisNCT02726269Asofarma de México S.A de C.V.230
已完成
不适用
Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori EradicationHelicobacter Pylori InfectionNCT01306786The University of Hong Kong800
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori InfectionHelicobacter PyloriNCT04198363Takeda510